한글목차

혈액 스크리닝 시장 규모는 2025년 38억 8,000만 달러에서 2026년부터 2034년까지 CAGR 12.62%로 성장하여 2034년에는 113억 1,000만 달러에 달할 것으로 예측됩니다.

감염성 질환의 확산과 안전한 수혈에 대한 수요 증가를 배경으로 혈액 스크리닝 시장은 괄목할 만한 성장이 예상됩니다. 혈액 검사는 병원체, 항체, 기타 유해물질을 검출하여 혈액제제의 안전성을 확보하는 중요한 과정입니다. 의료 서비스 제공자가 환자의 안전을 최우선으로 여기고 규제 당국이 엄격한 검사 요건을 시행함에 따라 첨단 혈액 검사 기술의 채택이 증가할 것으로 예상됩니다. 이 시장에서는 혈액 스크리닝 프로세스의 검출 능력을 향상시키는 핵산 검사(NAT) 및 다중 분석과 같은 보다 효율적이고 정확한 검사 방법으로의 전환이 이루어지고 있습니다.

또한, 혈액 검사 기술의 발전은 시장 내 혁신을 촉진하고 있습니다. 자동화 시스템 및 현장 검사 솔루션의 개발은 혈액 검사 수행 방식을 변화시켜 보다 빠른 결과와 워크플로우 효율을 향상시키고 있습니다. 이러한 혁신은 검사 정확도를 높일 뿐만 아니라 결과 처리 시간을 단축하고, 의료진이 환자 치료에 대한 적시 판단을 내릴 수 있도록 돕습니다. 혈액 스크리닝 시장이 계속 진화하는 가운데, 지속적인 연구 개발 노력은 의료 서비스 제공자의 다양한 요구를 충족시키기 위한 검사 솔루션의 범위를 확장하는 데 중요한 역할을 할 것입니다.

또한, 예방 의료와 조기 발견에 대한 중요성이 높아지면서 혈액 검진에 대한 관심이 높아지고 있습니다. 정기적인 건강검진의 중요성에 대한 인식이 높아짐에 따라, 환자들은 건강 문제가 악화되기 전에 잠재적인 문제를 파악할 수 있는 혈액 검사를 찾는 경향이 높아지고 있습니다. 의료 서비스 제공자들도 만성질환 관리와 환자 예후 개선에 있어 적극적인 검진의 가치를 인식하고 있습니다. 혈액 스크리닝 시장이 계속 성장하고 있는 가운데, 기술 발전, 환자 인식의 향상, 예방 의료에 대한 관심이 결합되어 향후 성장을 견인하는 데 중요한 역할을 할 것입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 혈액 스크리닝 시장 : 기술별

제5장 세계의 혈액 스크리닝 시장 : 제품별

제6장 세계의 혈액 스크리닝 시장 : 지역별

제7장 경쟁 구도

제8장 기업 개요

영문목차

The Blood Screening Market size is expected to reach USD 11.31 Billion in 2034 from USD 3.88 Billion (2025) growing at a CAGR of 12.62% during 2026-2034.

The blood screening market is poised for significant growth, driven by the increasing prevalence of infectious diseases and the rising demand for safe blood transfusions. Blood screening is a critical process that ensures the safety of blood products by detecting pathogens, antibodies, and other harmful substances. As healthcare providers prioritize patient safety and regulatory bodies enforce stringent testing requirements, the adoption of advanced blood screening technologies is expected to rise. This market is witnessing a shift towards more efficient and accurate testing methods, including nucleic acid testing (NAT) and multiplex assays, which enhance the detection capabilities of blood screening processes.

Moreover, advancements in blood screening technologies are propelling innovation within the market. The development of automated systems and point-of-care testing solutions is transforming the way blood screening is conducted, allowing for faster results and improved workflow efficiency. These innovations not only enhance the accuracy of testing but also reduce the turnaround time for results, enabling healthcare providers to make timely decisions regarding patient care. As the blood screening market continues to evolve, ongoing research and development efforts will play a crucial role in expanding the range of testing solutions available to meet the diverse needs of healthcare providers.

Additionally, the growing emphasis on preventive healthcare and early detection is shaping the blood screening landscape. As awareness of the importance of regular health screenings increases, patients are more likely to seek out blood tests that can identify potential health issues before they escalate. Healthcare providers are also recognizing the value of proactive screening in managing chronic conditions and improving patient outcomes. As the blood screening market continues to grow, the combination of technological advancements, increasing patient awareness, and a focus on preventive care will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA & EIA )
• Next Generation Sequencing (NGS)
• Western Blotting (WB)

By Product

• Reagent
• Instrument

COMPANIES PROFILED

• Abbott, Danaher Corporation Beckman Coulter, Becton Dickinson and Company, BioRad Laboratories, Inc, HoffmanLa Roche Ltd, Grifols, SA, OrthoClinical Diagnostics, Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc, SOFINA sa Biomerieux

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLOOD SCREENING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Nucleic Acid Amplification Test (NAT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. ELISA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chemiluminescence Immunoassay (CLIA & EIA ) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Next Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Western Blotting (WB) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLOOD SCREENING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Reagent Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Instrument Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLOOD SCREENING MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Technology
  • 6.2.2 By Product
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Technology
  • 6.3.2 By Product
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Technology
  • 6.4.2 By Product
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Technology
  • 6.5.2 By Product
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Technology
  • 6.6.2 By Product
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLOOD SCREENING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Danaher Corporation (Beckman Coulter)
  • 8.2.3 Becton Dickinson And Company
  • 8.2.4 Bio-Rad LaboratoriesInc
  • 8.2.5 Hoffman-La Roche Ltd
  • 8.2.6 Grifols, S.A
  • 8.2.7 Ortho-Clinical DiagnosticsInc
  • 8.2.8 Siemens Healthcare GmbH
  • 8.2.9 Thermo Fisher ScientificInc
  • 8.2.10 SOFINA S.A (Biomerieux)